Awareness of smoking in adolescents with inflammatory bowel disease
More details
Hide details
Department of Paediatric Gastroenterology and Nutrition, Medical University, Warsaw, Poland
Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, Jagiellonian University, Kraków, Poland
Department of Paediatric Neurosurgery and Traumatology, Medical University, Warsaw, Poland
Student Research Association, Department of Paediatric Gastroenterology and Nutrition, Medical University, Warsaw, Poland
Corresponding author
Kinga Kowalska-Duplaga   

Uniwersytet Jagielloński Collegium Medicum, Department of Pediatrics, Gastroenterology and Nut, 30-663, Kraków, Poland
Ann Agric Environ Med. 2020;27(1):61-65
Introduction and objectives:
Inflammatory bowel disease (IBD) is long life disease that results from an interaction between a polygenetic predisposition and environmental factors, including smoking. The aim of this study was to evaluate beliefs about and awareness of smoking among adolescents with IBD compared to healthy controls.

Material and methods:
Patients with IBD, Crohn’s disease (CD) and ulcerative colitis (UC), and healthy controls were asked to complete a questionnaire on demographic data and smoking status. The questionnaire also included data on beliefs and awareness of smoking-related health effects, including effects on IBD.

A total of 139 IBD patients and 108 controls were enrolled in the study. Of the IBD patients, 17/139 (12.2%) were smokers compared to 18/108 (16.7%) of controls (p=0.3). Patients with IBD were nine times more likely to be everyday smokers than occasional smokers (OR=9.2, 95% CI: 1.9- 45.1, p=0.004). No difference was found between patients with CD and UC in their answers to the question of whether “smoking increases the risk for surgery in your type of IBD” (17/28 (60.7%) vs. 10/29 (34.5%), respectively (p=0.047). More patients with CD than UC were aware of the risks of smoking on their disease: extra-intestinal manifestations and disease exacerbation, OR=11.3 (95% CI: 4.1 – 30.9; p=0.000) and OR=19.3 (95% CI: 6.7 – 55.1; p=0.000), respectively.

The data obtained demonstrated that adolescents with CD are much more aware of the role of smoking on CD than are their peers with UC; however, this awareness is still unsatisfactory. Therefore, there is an unmet need to implement better anti-smoking strategies for this group of patients.

Shouval DS, Rufo PA. The Role of environmental factors in the pathogenesis of inflammatory bowel diseases. JAMA Pediatr. 2017; 171: 999.
Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect. J Crohn’s Colitis. 2014; 8: 717–725.
van der Slot K, Amini M, Peters V, Dijkstra G, Alizadeh BZ. Inflammatory bowel diseases: review of known environmental protective and risk factors involved. Inflamm Bowel Dis. 2017; 9: 1499–1509.
Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006; 81: 1462–71.
Cosnes J, Beaugerie L, Carbonnel F, Gendre J. Smoking cessation and the course of Crohn’s disease: An intervention study. Gastroenterology. 2001; 120: 1093–9.
Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008; 23: 1213–21.
Cosnes, Carbonnel, Carrat, Beaugerie, Cattan, Gendre. Effects of current and former cigarette smoking on the clinical course of Crohn’s disease. Aliment Pharmacol Ther. 1999; 13: 1403–11.
Persson PG, Ahlbom A, Hellers G. Inflammatory bowel disease and tobacco smoke--a case-control study. Gut. 1990; 31: 1377–81.
Yadav P, Ellinghaus D, Rémy G, Freitag-Wolf S, Cesaro A, Degenhardt F, et al. Genetic factors interact with tobacco smoke to modify risk for inflammatory bowel disease in humans and mice. Gastroenterology. 2017; 153: 550–65.
Helbig KL, Nothnagel M, Hampe J, Balschun T, Nikolaus S, Schreiber S, et al. A case-only study of gene-environment interaction between genetic susceptibility variants in NOD2 and cigarette smoking in Crohn’s disease aetiology. BMC Med Genet. 2012; 13: 14.
Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ, et al. Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis. 2012; 18: 1092–100.
Rom O, Avezov K, Aizenbud D, Reznick AZ. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol. 2013; 187: 5–10.
Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastián VP, Álvarez-Lobos MM, et al. Impact of cigarette smoking on the gastrointestinal tract inflammation: Opposing effects in Crohn’s disease and ulcerative colitis. Front. Immunol. 2018; 9: 74.
Savin Z, Kivity S, Yonath H, Yehuda S. Smoking and the intestinal microbiome. Arch Microbiol. 2018; 200: 677–84.
Gallus S, Lugo A, La Vecchia C, Boffetta P, Chaloupka FJ, Colombo P, et al. Pricing policies and control of tobacco in Europe (PPACTE) project. Eur J Cancer Prev. 2014; 23: 177–85.
Nowak M, Papiernik M, Mikulska A, Czarkowska-Paczek B. Smoking, alcohol consumption, and illicit substances use among adolescents in Poland. Subst Abuse Treat Prev Policy. 2018; 13: 42.
General US. U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking–attributable disease. A report of the surgeon general. Public Heal Serv Off Surg Gen 2010.
Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, De Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014; 58: 795–806.
Ducharme-Bénard S, Côté-Daigneault J, Lemoyne M, Orlicka K, Lahaie R, Weber A, et al. Patients with inflammatory bowel disease are unaware of the impact of smoking on their disease. J Clin Gastroenterol. 2016; 50: 490–7.
De Bie C, Ballet V, Hendriks N, Coenen S, Weyts E, Van Assche G, et al. Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 42: 1294–302.
Saadoune N, Peyrin-Bieroulet L, Baumann C, Bigard M.-A, Wirth N, Martinet Y. Beliefs and behaviour about smoking among inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2015; 27: 797–803.
Ryan W. Patients with crohn’s disease are unaware of the risks that smoking has on their disease. J Gastrointest Surg. 2003; 7: 706–11.
Pesce G, Marcon A, Calciano L, Perret JL, Abramson MJ, Bono R, et al. Time and age trends in smoking cessation in Europe. Manzoli L, editor. PLoS One 2019; 14: e0211976.
Wahed M, Goodhand JR, West O, McDermott A, Hajek P, Rampton DS. Tobacco dependence and awareness of health risks of smoking in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011; 23: 90–4.
(WHO) WHO. The current status of the tobacco epidemic in Poland. Copenhagen WHO Reg Off Eur. 2009.
Haug S, Schaub MP, Schmid H. Predictors of adolescent smoking cessation and smoking reduction. Patient Educ Couns. 2014; 95: 378–83.
Journals System - logo
Scroll to top